Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

http://www.wikidata.org/entity/Q39893068

about

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Immune cell promotion of metastasis Targeting regulatory T cells in cancer Suppression, subversion and escape: the role of regulatory T cells in cancer progression Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal.The role of regulatory T cells in cancer.CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis.Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma.CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells Stromal reengineering to treat pancreas cancer CCR5 dictates the equilibrium of proinflammatory IL-17+ and regulatory Foxp3+ T cells in fungal infection.Pancreatic cancer, inflammation, and microbiome.The role of chemoattractant receptors in shaping the tumor microenvironment.Complex role for the immune system in initiation and progression of pancreatic cancer.Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switch Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model.Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.An aberrant thymus in CCR5-/- mice is coupled with an enhanced adaptive immune response in fungal infection.Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas.Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts.Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion.The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion TIGIT predominantly regulates the immune response via regulatory T cells.Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma TLR9 ligation in pancreatic stellate cells promotes tumorigenesis RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

P2860

Q26798402-758B1956-B79D-4ABC-8620-29EE81F0CF0E Q26991724-0984A356-C5B6-4A20-A7F4-5C54C4BCE66A Q27022348-8BC75C11-2D89-47BB-BB3A-2F162234F81D Q27026151-5E014EFA-DAA3-4A92-8FA1-472DBECE8EC7 Q28393614-A3E44D15-EF80-482B-9FC0-EF0C325A6779 Q28741084-3799A4BF-DAA4-4118-8495-BEE0212F1B00 Q30577136-2581025E-F59D-43F8-AE78-E327BE717BE0 Q33631986-CB39EAA4-574F-4B7C-A8C3-78C751E96DB3 Q33677606-E5DB54C2-655B-47AA-8120-1F6F4B936FDA Q33723063-95B58BA9-2897-4EC9-A9CF-B532202A0B8F Q33753714-11F566CE-0984-489A-8F38-3300CADD6D8A Q33816303-1D677B89-40FB-4108-B3FC-921DC6BCF070 Q33827708-26E743A5-BDB5-4434-B0CF-9573B3EA93B6 Q33839741-BDF746D5-F40F-48F7-9E93-0E691481AC5A Q33956107-20A5E54E-81B9-4B40-9247-A3B38F7DB43F Q33993124-265BB3E8-1B8B-44D4-9AFA-57AF5E0D6E1E Q34093784-FA436F7E-5CD0-474B-81FC-CBEDC11CEC7D Q34146406-1496EB1B-5C66-4C39-973E-FC11B9EF9C9A Q34205181-94467C8B-4A7C-4A6B-A524-1B51C9220601 Q34261494-9E247437-25C9-4C5F-B465-9766B6FC217E Q34495723-1C3264CF-9EA8-4442-BFFF-9BFC170C92BB Q34541853-5F563952-0277-43E0-8043-B3E6C976C276 Q34757261-A77070D5-91FD-4A43-8576-589D7510B73D Q34994967-377E9C39-23C6-4A47-84FE-D972708BA8D4 Q35035564-C3A397DA-11E6-4D1D-8F66-BA3C1D374B3B Q35051508-1425142D-CA77-4523-8CBF-5DE34946C54E Q35384216-BDDBE3D1-5E93-447A-8FDE-4ECFC63D6FA9 Q35512402-C726E1E8-6BD5-4590-9717-31171C396C39 Q35731399-60FFD714-0EB6-42FF-8EB5-D70994A0A7A5 Q35739397-9237575A-11F4-44CE-B779-D6541AC70EF7 Q35870682-4C10A683-48AF-4D56-827E-020ECA91FC10 Q36057441-A6931144-DC9E-4F0D-B191-DFD814FACF1F Q36107928-4D9619D4-E4B1-4B4B-B094-03238316CE33 Q36202213-4A238BDA-BA9E-49C2-8CDF-67573D8391CA Q36266506-C641563A-62DE-4DB8-95C7-E068566F26C8 Q36285576-E053C846-9D97-4227-AE11-573677654745 Q36286020-419B5A68-6E04-4009-B3EE-29F05A6DB42B Q36309612-7A8F0E5F-0538-49CB-99B2-B8B87F46B2B1 Q36715205-14D44001-7337-4B81-9F57-EB2D9B4EF124 Q36821572-A66EC869-A5F7-46DE-874C-E32E587B354B

P2860

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.

http://www.wikidata.org/entity/Q39893068

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@en

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@nl

type

label

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@en

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@nl

prefLabel

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@en

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@nl

P1433

Q39893068-535CC26B-A33D-4C63-8B18-237294DE2203

P1476

Q39893068-87902895-EECD-4BD9-9F5E-14ED9EDDF595

P2093

Q39893068-17624078-9876-4D67-B289-E270922DC234

Q39893068-3C026514-E7BA-468A-A6C6-FCF05AE7937C

Q39893068-435979A4-8750-4FD0-B837-79F51C913665

Q39893068-4CEBD38F-97C0-4632-A8F8-874D191B3727

Q39893068-4D3FE6F1-8B45-42BB-9AAE-A0C2E17C36D3

Q39893068-6DAAF294-F4D5-49AF-BCD4-E895F5B8DD9B

Q39893068-B5A1EFF3-6DD3-4C60-B2A0-16F232C9CBB1

Q39893068-C9E9ED6A-CA55-480F-BE24-8E3E5F59E02D

Q39893068-DDA4D810-D46B-4E97-BDDD-9445C1EF9B5D

P2860

Q39893068-03C403E7-3910-475E-88F0-1ECEEF72AC35

Q39893068-054B8C09-33B8-49B9-94CF-A0366C94A281

Q39893068-0CD05311-3D9A-4C8A-BCA5-A34A2BAD3393

Q39893068-103C801B-680E-4FC2-BD95-71D4848BBD60

Q39893068-1058F77E-A25C-4F11-ADEF-AC8E06556000

Q39893068-11F2ACD4-024A-4B8E-A7C1-407E85FD6958

Q39893068-12420667-1210-43F0-B656-9687CBD5B26C

Q39893068-166986DC-A2B4-4DB2-84DD-585F49793428

Q39893068-17D6F30A-6911-40E9-811D-38CC34EAD576

Q39893068-1D0794BD-2371-47A8-A607-B75B032803EB

P304

Q39893068-7DFEF9D1-E8BE-48DF-AA0D-ECFE1B8B411E

P31

Q39893068-2CF437A9-2EF7-4828-9223-1A88EBB718F3

P356

Q39893068-6BA62EF1-619F-4465-8189-BEC53E09D10F

P407

Q39893068-6EFF9F30-691F-4618-8F9D-3345320E3A0F

P433

Q39893068-587B9252-B39A-4FCC-AEF8-7CDDED202888

P478

Q39893068-0C5C2C38-1F1C-4428-A685-3473461EDDF4

P577

Q39893068-C55A525B-2A64-4271-8FDD-1B50AC527E8F

P5875

Q39893068-5388E0E7-422D-4D63-9632-E4D1B02F80DE

P698

Q39893068-C27D6418-0EA0-4E01-A6CD-362FCDBEAFEE

P932

Q39893068-10D0BE8D-A4BE-452D-A557-4B5EA05AF47F

P356

JIMMUNOL.182.3.1746

P1433

Journal of Immunology

P1476

Disruption of CCR5-dependent h ...... ne model of pancreatic cancer.

@en

P2093

Brian A Belt

http://www.w3.org/2001/XMLSchema#string

Brian Flaherty

http://www.w3.org/2001/XMLSchema#string

Chyi-Song Hsieh

http://www.w3.org/2001/XMLSchema#string

David C Linehan

http://www.w3.org/2001/XMLSchema#string

Marcus C B Tan

http://www.w3.org/2001/XMLSchema#string

Narendra Sankpal

http://www.w3.org/2001/XMLSchema#string

Peter S Goedegebuure

http://www.w3.org/2001/XMLSchema#string

Timothy J Eberlein

http://www.w3.org/2001/XMLSchema#string

William E Gillanders

http://www.w3.org/2001/XMLSchema#string

P2860

Cre-lox-regulated conditional RNA interference from transgenes

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Control of regulatory T cell development by the transcription factor Foxp3

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

Regulatory T cells and immune tolerance

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.

P304

1746-1755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.182.3.1746

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23803372

http://www.w3.org/2001/XMLSchema#string

P698

19155524

http://www.w3.org/2001/XMLSchema#string

P932

3738070

http://www.w3.org/2001/XMLSchema#string